A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1) von Lindman, H., Andersson, M., Ahlgren, J., Balslev, E., Sverrisdottir, A., Holmberg, S.B., Bengtsson, N.O., Jacobsen, E.H., Jensen, A.B., Hansen, J., Tuxen, M.K., Malmberg, L., Villman, K., Anderson, H., Ejlertsen, B., Bergh, J., Blomqvist, C.

Volltext

CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use von DUFFY, M.J., BONFRER, J.M., KULPA, J., RUSTIN, G.J.S., SOLETORMOS, G., TORRE, G.C., TUXEN, M.K., ZWIRNER, M.

Volltext

Exploratory Phase III Study of Paclitaxel and Cisplatin Versus Paclitaxel and Carboplatin in Advanced Ovarian Cancer von NEIJT, J. P, ENGELHOLM, S. A, TUXEN, M. K, SØRENSEN, P. G, HANSEN, M, SESSA, C, DE SWART, C. A. M, HIRSCH, F. R, LUND, B, VAN HOUWELINGEN, H. C

Volltext

Abstract S6-03: DBCG 07-READ: A randomized phase III trial comparing six cycles of docetaxel and cyclophosphamide (DC) to three cycles of epirubicin and cyclophosphamide followed b... von Ejlertsen, B, Tuxen, MK, Jakobsen, EH, Jensen, M-B, Knoop, AS, Hoejris, I, Ewertz, M, Balslev, E, Vestlev, PM, Kenholm, J, Nielsen, DL, Bechmann, T, Andersson, M, Cold, S, Nielsen, HM, Maae, E, Carlsen, D, Mouridsen, HT

Volltext

Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group study von Rustin, G. J. S., Nelstrop, A. E., Tuxen, M. K., Lambert, H. E.

Volltext

Serum tumour marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy von TUXEN, M. K, SÖLETORMOS, G, DOMBERNOWSKY, P

Volltext

Tumor markers in the management of patients with ovarian cancer von Tuxen, Malgorzata K., Sölétormos, György, Dombernowsky, Per

Volltext

Neurotoxicity secondary to antineoplastic drugs von Tuxen, Malgorzata K., Hansen, Steen Werner

Volltext

TIMP-1 and responsiveness of estrogen receptor negative breast cancer to preoperative epirubicin and cyclophosphamide with or without gefitinib von Hertel, PB, Brünner, N, Jørgensen, LA, Petersen, MB, Ingvar, C, Jacobsen, EH, Sætersdal, AB, Tuxen, MK, Nielsen, BS, Mouridsen, HT, Ejlertsen, B

Volltext

Assessment of Biological Variation and Analytical Imprecision of CA 125, CEA, and TPA in Relation to Monitoring of Ovarian Cancer von Tuxen, Malgorzata K., Sölétormos, György, Petersen, Per Hyltoft, Schiøler, Vibeke, Dombernowsky, Per

Volltext

Serum tumor marker CA 125 for monitoring ovarian cancer during follow-up von Tuxen, M. K., SöLétormos, G., Dombernowsky, P.

Volltext

The role of second-look laparotomy in the long-term survival in ovarian cancer von TUXEN, M. K, STRAUSS, G, LUND, B, HANSEN, M

Volltext

Interpretation of Sequential Measurements of Cancer Antigen 125 (CA 125), Carcinoembryonic Antigen (CEA) and Tissue Polypeptide Antigen (TPA) Based on Analytical Imprecision and Bi... von Tuxen, Malgorzata K., Sölétormos, György, Petersen, Per Hyltoft, Dombernowsky, Per

Volltext

Biological variation and analytical imprecision of CA 125 in patients with ovarian cancer von Tuxen, M. K., Rustin, G. J. S., Dombernowsky, P., Sölétormos, G., Nelstrop, A. E.

Volltext

Oral etoposide in elderly previously untreated ovarian cancer patients with residual disease von TUXEN, M. K., LUND, B., HANSEN, O. P., BERTELSEN, K., HANSEN, M.

Volltext

Second-look laparotomy in the management of patients after radical surgery for ovarian cancer von Tuxen, M. Kolyszko, Lund, B., Hansen, O. Paaske, Hansen, M.

Volltext

Factors associated with condom use during sexual intercourse with a new partner among Scandinavian women von Tatla, Manrinder Kaur, Faber, Mette Tuxen, Hansen, Bo T., Arnheim-Dahlström, Lisen, Munk, Christian, Nygård, Mari, Kjær, Susanne K.

Volltext

Markers of collagen synthesis is related to blood pressure and vascular hypertrophy: a LIFE substudy von OLSEN, M. H, CHRISTENSEN, M. K, DIGE-PETERSEN, H, ROKKEDA, J, IBSEN, H, WACHTELL, K, TUXEN, C, FOSSUM, E, BANG, L. E, WIINBERG, N, DEVEREUX, R. B, KJELDSEN, S. E, HILDEBRANDT, P

Volltext